English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/200545
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

AuthorsCuadrado-Tejedor, M.; Garcia-Barroso, Carolina; Sánchez-Arias, Juan A.; Rabal, Obdulia; Pérez-González, Marta; Mederos, Sara; Ugarte, Ana; Franco, Rafael; Segura, Víctor; Perea, Gertrudis CSIC ORCID; Oyarzabal, Julen; García-Osta, A.
KeywordsAlzheimer's disease
Clinical pharmacology
Drug development
Drug therapy
Synaptic transmission
Target validation
Issue Date2017
PublisherSpringer Nature
American College of Neuropsychopharmacology
CitationNeuropsychopharmacology 42: 524-539 (2017)
AbstractThe targeting of two independent but synergistic enzymatic activities, histone deacetylases (HDACs, class I and HDAC6) and phosphodiesterase 5 (PDE5), has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs. We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB) induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation. This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice. Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission. Thus, CM-414 may serve as the starting point to discover balanced dual inhibitors with an optimal efficacy and safety profile for clinical testing on AD patients.
Publisher version (URL)http://dx.doi.org/10.1038/npp.2016.163
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.